Authors:
Somlo, G
Doroshow, JH
Synold, T
Longmate, J
Reardon, D
Chow, W
Forman, SJ
Leong, LA
Margolin, KA
Morgan, RJ
Raschko, JW
Shibata, SI
Tetef, ML
Yen, Y
Kogut, N
Schriber, J
Alvarnas, J
Citation: G. Somlo et al., High-dose paclitaxel in combination with doxorubicin, cyclophosphamide andperipheral blood progenitor cell rescue in patients with high-risk primaryand responding metastatic breast carcinoma: toxicity profile, relationshipto paclitaxel pharmacokinetics and short-term outcome, BR J CANC, 84(12), 2001, pp. 1591-1598
Authors:
Morgan, RJ
Braly, P
Leong, L
Shibata, S
Margolin, K
Somlo, G
McNamara, M
Longmate, J
Schinke, S
Raschko, J
Nagasawa, S
Kogut, N
Najera, L
Johnson, D
Doroshow, JH
Citation: Rj. Morgan et al., Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracilin previously treated patients with advanced ovarian cancer: Long-term follow-up, GYNECOL ONC, 77(3), 2000, pp. 433-438
Authors:
Morgan, RJ
Braly, P
Cecchi, G
Leong, L
Shibata, S
Margolin, K
Somlo, G
McNamara, M
Longmate, J
Schinke, S
Raschko, J
Nagasawa, S
Kogut, N
Parker, P
Stein, A
Cho, J
Smith, E
Coluzzi, P
Najera, L
Johnson, D
Womack, E
Doroshow, JH
Citation: Rj. Morgan et al., Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up, GYNECOL ONC, 75(3), 1999, pp. 419-426